• 1
    World Health Organization. World Health Report 2003: Shaping the Future. World Health Organization, Geneva, 2003.
  • 2
    World Health Organization. Prevention of Mental Disorders. Effective Interventions and Policy Options. World Health Organization, Geneva, 2004; 4951.
  • 3
    World Health Organization. Country Reports and Charts. World Health Organization, Geneva, 2007.
  • 4
    ISTAT. Aggiornamento sistema informativo giustizia. Nota per la stampa, 9 settembre 2008 (Updating the Justice information system network. Note for the Press, September the 9th, 2008). Rome, Italy: Istituto Nazionale di Statistica (National Institute of Statistics), 2009.
  • 5
    Nock MK, Borges G, Bromet EJ, Cha CB, Kessler RC, Lee S. Suicide and suicidal behavior. Epidemiol. Rev. 2008; 30: 133154.
  • 6
    Rihmer Z. Suicide risk in mood disorders. Curr. Opin. Psychiatry 2007; 20: 1722.
  • 7
    Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA 2003; 290: 15171519.
  • 8
    Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J. Clin. Psychiatry 2003; 64 (Suppl. 5): 4452.
  • 9
    Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006; 8: 625639.
  • 10
    Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 14671473.
  • 11
    Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J. Clin. Psychiatry 1998; 59: 405414.
  • 12
    Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr. Scand. 2001; 104: 163172.
  • 13
    Meltzer HY, Alphs L, Green AI et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003; 60: 8291. [erratum 735].
  • 14
    Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry 2001; 34: 132136.
  • 15
    Müller-Oerlinghausen B. Arguments for the specificity of the antisuicidal effect of lithium. Eur. Arch. Psychiatry Clin. Neurosci. 2001; 251 (Suppl. 2): II72II75.
  • 16
    Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J. Clin. Psychiatry 2007; 68: 380383.
  • 17
    Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr. Serv. 1989; 49: 10291033.
  • 18
    Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res. 2005; 73: 139145.
  • 19
    Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br. J. Psychiatry 1999; 175: 576580.
  • 20
    Haas SJ, Dennekamp MN, Wolfe R, Vos T. Beware the meta-analysis – clozapine and suicidal ideation. Schizophr. Res. 2006; 86: 331332.
  • 21
    Kielholz P, Battegay R. Treatment of depressive states with special consideration of tofranil, a new antidepressant. Schweiz. Med. Wochenschr. 1958; 88: 763767.
  • 22
    Schneeweiss S, Patrick AR, Solomon DH et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch. Gen. Psychiatry 2010; 67: 497506.
  • 23
    Stone M, Laughren T, Jones ML et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009; 339: b2880.
  • 24
    Mann JJ, Emslie G, Baldessarini RJ et al. ACNP Task Force Report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006; 31: 473492.
  • 25
    Isacsson G, Rich CL, Jureidini J, Raven M. The increased use of antidepressants has contributed to the worldwide reduction in suicide rates. Br. J. Psychiatry 2010; 196: 429433.
  • 26
    Wernicke JF, Sayler ME, Koke SC, Pearson DK, Tollefson GD. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. Depress. Anxiety 1997; 6: 3139.
  • 27
    Kenchadze VG, Chkonia ED, Sikharulidze GG. Increased risk of suicide in patients with agitated depression. Georgian Med. News 2009; 177: 4751 (in Russian).
  • 28
    Greenberger D, Padesky CA. Mind Over Mood. Guilford Press, New York, 1995.
  • 29
    Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria (RDC). Biometrics Research Evaluation Center, New York State Psychiatric Institute, New York, 1975.
  • 30
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR). American Psychiatric Association, Washington, DC, 2000.
  • 31
    Benazzi F. Agitated depression: a valid depression subtype? Prog. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 12791285.
  • 32
    Akiskal HS, Mallya G. Criteria for the ‘soft’ bipolar spectrum: treatment implications. Psychopharmacol. Bull. 1987; 23: 6873.
  • 32
    Mathers CD, Lopez AD, Murray CJL. The burden of disease and mortality by condition: Data, methods, and results for 2001. In : LopezAD, MathersCD, EzzatiM, JamisonDT, MurrayCJL (eds). Global Burden of Disease and Risk Factors. Oxford University Press and World Bank, New York, 2006; 45240.
  • 33
    Ösby U, Brandt L, Correia N, Ekbom A, Sparén P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 2001; 58: 844850.
  • 34
    Tondo L, Isacsson G, Baldessarini R. Suicidal behavior in bipolar disorder: risk and prevention. CNS Drugs 2003; 17: 491511.
  • 35
    Khan A, Leventhal RM, Khan S, Brown WA. Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J. Affect. Disord. 2002; 68: 183190.
  • 36
    Noyes R Jr. Suicide and panic disorder: a review. J. Affect. Disord. 1991; 22: 111.
  • 37
    Isometsä ET, Aro HM, Henriksson MM, Heikkinen ME, Lönnqvist JK. Suicide in major depression in different treatment settings. J. Clin. Psychiatry 1994; 55: 523527.
  • 38
    Koukopoulos A, Albert MJ, Sani G, Koukopoulos AE, Girardi P. Mixed depressive states: nosologic and therapeutic issues. Int. Rev. Psychiatry 2005; 17: 2137.
  • 39
    Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated ‘unipolar’ depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J. Affect. Disord. 2005; 85: 245258.
  • 40
    Balázs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J. Affect. Disord. 2006; 91: 133138.
  • 41
    Koukopoulos A, Faedda G, Proietti R, D'Amico S, de Pisa E, Simonetto C. Un syndrome dépressif mixte. Encéphale 1992; 18: 1921.
  • 42
    Jameison GR. Suicide and mental disease: a clinical analysis of one hundred cases. Arch. Neurol. Psychiatry 1936; 36: 112.
  • 43
    Kotin J, Goodwin FK. Depression during mania: clinical observation and theoretical implications. Am. J. Psychiatry 1972; 129: 679686.
  • 44
    Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J. Affect. Disord. 2006; 94: 313.
  • 45
    Valtonen HM, Suominen K, Haukka J et al. Differences in incidence of suicide attempts during phases of bipolar I and II disorders. Bipolar Disord. 2008; 10: 588596.
  • 46
    Pompili M, Innamorati M, Giupponi G et al. Prädiktion des Suizidrisikos bei bipolar und unipolar depressiven Patienten. Wechselwirkung von Temperament und Persönlichkeit. Nervenarzt 2009; 80: 315323.
  • 47
    Bocchetta A, Fadda D, Satta G, Del Zompo M, Gessa GL, Cocco P. Long-term lithium treatment and survival from external causes including suicide. J. Clin. Psychopharmacol. 2007; 27: 544546.
  • 48
    Ohgami H, Terao T, Shiotsuki I, Ishii N, Iwata N. Lithium levels in drinking water and risk of suicide. Br. J. Psychiatry 2009; 194: 464465.
  • 49
    Terao T, Goto S, Inagaki M, Okamoto Y. Even very low but sustained lithium intake can prevent suicide in the general population? Med. Hypotheses 2009; 73: 811812.
  • 50
    Pompili M, Rihmer Z, Akiskal HS et al. Temperament and personality dimensions in suicidal and nonsuicidal psychiatric inpatients. Psychopathology 2008; 41: 313321.
  • 51
    Rihmer A, Rozsa S, Rihmer Z, Gonda X, Akiskal KK, Akiskal HS. Affective temperaments, as measured by TEMPS-A, among nonviolent suicide attempters. J. Affect. Disord. 2009; 116: 1822.
  • 52
    Akiskal HS, Placidi GF, Maremmani I et al. TEMPS-I: delineating the most discriminant traits of the cyclothymic, depressive, hyperthymic and irritable temperaments in a nonpatient population. J. Affect. Disord. 1998; 51: 719.
  • 53
    Kochman FJ, Hantouche EG, Ferrari P, Lancrenon S, Bayart D, Akiskal HS. Cyclothymic temperament as a prospective predictor of bipolarity and suicidality in children and adolescents with major depressive disorder. J. Affect. Disord. 2005; 85: 181189.
  • 54
    Smith EG, Craig TJ, Ganoczy D, Walters HM, Valenstein M. Treatment of veterans with depression who died by suicide: timing and quality of care at last Veterans Health Administration visit. J. Clin. Psychiatry 2010. doi:10.4088/JCP.09m05608blu.
  • 55
    Busch KA, Fawcett J, Jacobs DG. Clinical correlates of inpatient suicide. J. Clin. Psychiatry. 2003; 64: 1419.
  • 56
    Olgiati P, Serretti A, Colombo C. Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. Depress. Anxiety 2006; 23: 389397.